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Abstract
Transthyretin (also known as prealbumin) is an important transport protein, which plays 
an essential role in the binding of thyroid hormones and retinol with varying affinities in 
mammalian, as well as avian species. The determination of transthyretin concentrations may 
be used as a diagnostic tool for some disease conditions in humans, but is more often used 
as a nutritional marker to assess protein-calorie malnutrition and as prognostic indicator 
in critically ill patients. Transthyretin has shorter half-life (2–3 days) than that of albumin 
and belongs to negative acute phase proteins. This may complicate the use of transthyre-
tin as a nutritional marker and the interpretation of results in the diagnosis of diseases.  
Although some studies have been carried out to determine the usefulness of transthyretin 
in selected disease conditions and disorders also in animals, it is a relatively rarely used 
parameter to evaluate health state and illness in veterinary medicine. The usefulness of 
transthyretin in the diagnosis of diseases and evaluation of nutritional status in humans 
and animals are reviewed in this article, including the laboratory assays available to mea-
sure its concentrations and the possible clinical application of the results, as well as its 
usefulness as a prognostic indicator in some disease conditions.
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1. Introduction
Transthyretin is an important transport protein of the blood, which was originally named 
prealbumin because it migrates faster than albumin, and is visible as a band anodic to the 
main albumin fraction on electrophoretic gels [1]. According to Hamilton and Benson [2], this 
property is attributed to human prealbumin, not to bovine. Kaneko [3] reported that prealbu-
min is not always visualized on electrophoretograms and may not exist in all animal species. 
In the 1980s, the name was changed to transthyretin (TTR) describing its ability to bind both 
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thyroid hormones and retinol-binding protein (RBP) [4]. Moreover, transthyretin is one of the 
precursors, which may be found in amyloid deposits [5]. In humans, analyses of the concen-
trations of TTR in serum are recommended by some investigators as a screening marker for 
inflammation, malnutrition, or both [6]. In animals, there are only scarce literature data about 
this protein as a biomarker of health state and its use in the laboratory diagnosis [7].
2. Structure
Transthyretin is a small globular non-glycosylated tryptophan-rich protein of a homotetrameric 
structure, composed of four identical subunits with two thyroxine-binding sites per tetramer 
[8]. The binds for retinol-binding protein are placed at the surface of the molecule and do not 
interfere with thyroxin binding (Figure 1) [9]. Its molecular mass is of 54.98 kDa, which is small 
enough to penetrate the vascular wall and migrate into the extravascular space as easily as albu-
min or transferrin [10]. In some conditions, the transthyretin molecules may aggregate and form 
insoluble fibrillar deposits, which may be associated with amyloid diseases, predominantly 
senile systemic amyloidosis or neurodegenerative familial amyloidotic polyneuropathy [11, 12].
Figure 1. The three-dimensional structure of transthyretin displayed as a dimer (A) and a tetramer in complex with 
thyroxine (B) and retinol-binding protein (C) [103].
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3. Functions
Transthyretin is a serum protein with multiple functional properties [13]. The main  physio 
logical functions of TTR include the carriage of thyroid hormone and indirectly  vitamin A, 
which may promote the maturation of lymphocytes [14, 15]. Although each  monomer of the 
TTR molecule has two binding sites for thyroid hormones, the binding of one molecule of T3 
or T4 may reduce the binding affinity for the second site [6]. Moreover, the binding affinity 
for T3 is lower compared with that for T4. Transthyretin binds and transports  approximately 
15–20% of thyroid hormones circulating in the serum and up to 80% of thyroxine in the 
central nervous system (CNS) [16]. About 70% of thyroid hormones are transported by thy-
roxin-binding globulin (TBG), which is the major serum transport protein in humans [17]. The 
remaining part of thyroid hormones is transported by albumin. These proteins are respon-
sible for the transporting of thyroid hormones to cells and maintaining a large store of these 
hormones in the blood in a non-diffusible form [2]. Among animal species, the concentration 
of TBG in the dog is only 15% of those observed in humans [18]. Cats do not appear to have a 
high-affinity thyroid-binding protein such as TBG, but have only transthyretin and albumin 
[19]. Some other small molecules may bind in the thyroxine-binding sites of TTR, including 
some natural products, drugs or toxicants [20]. These interactions with TTR may be important 
when TTR becomes a major circulating thyroxine-binding protein, for example, in humans 
with complete or partial TBG deficiency, or when the concentration of thyroxine in the serum 
is markedly increased [21].
In addition to the binding and carriage of thyroid hormones, transthyretin has a more  important 
function, that is, the transport of retinol (vitamin A) through its association with retinol-binding 
protein (RBP) from its main storage site in the liver to target cells [22]. Retinol is bound to RBP, 
and then RBP binds to transthyretin. This binding of RBP to TTR was suggested to prevent the 
extensive loss of RBP, which is of low molecular weight and would be rapidly eliminated from 
plasma by glomerular filtration if it were not complexed to transthyretin [23, 24]. Although 
each of the four monomers has a binding site for RBP, the tetramer binds only one molecule of 
RBP with high affinity, and possibly a second with lower affinity [25].
Moreover, transthyretin acts as a negative acute phase reactant, serum concentrations of 
which fall due to decreased synthesis in inflammation, trauma, tissue injury or stress [26].
4. Synthesis
Transthyretin is synthesized mainly by hepatic parenchymal cells and in the choroid plexus 
of the brain, which has the highest concentration of TTR in the body [27, 28]. In cerebrospinal 
fluid, it is the second most abundant protein, which may be involved in the pathogenesis of 
Alzheimer´s disease, depression and lead intoxication [29]. Other tissues have been reported 
also to produce TTR, but in much lower concentrations [30]. Small amounts of TTR are also 
produced by retinal pigment epithelium and the pineal gland [31]. Transthyretin has also been 
found in adult pancreatic islet cells, enterochromaffin cells in the gastrointestinal mucosa, 
as well as kidney cells [32, 33]. Neoplastic tissues, including choroid plexus  papillomas, 
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 glucagonomas and gut carcinomas, have been reported also to secrete transthyretin [33]. 
During fetal life, TTR is synthesized by the embryonic yolk sac endothelium [34]. Any altera-
tion in energy-to-protein balance impairs the body mass reserves and causes early depression 
in the production of transthyretin [35].
The major sites of transthyretin degradation are the liver, muscles and skin, but a small 
amount of TTR may be catabolized by other tissues, including kidneys, adipose tissues, tes-
tes, as well as the gastrointestinal tract [36]. Transthyretin has a half-life in plasma of approxi-
mately 2 days, which is much shorter than that of albumin [37]. Transthyretin is therefore 
more sensitive to changes in protein-energy status, but its concentrations closely reflect the 
recent nutritional status rather than the overall nutritional support [38, 39].
5. Laboratory assays
Transthyretin is considered a more sensitive indicator of visceral protein status than albu-
min and transferrin because of its short half-life and low concentration in the body [40]. 
Conventionally, radial immunodiffusion and electroimmunodiffusion have been used for 
routine determination of transthyretin in humans [41]. Faster and more precise immunoneph-
elometric and immunoturbidimetric assays have been developed also, which are easily appli-
cable to many laboratory-automated equipments available in hospitals [6, 42]. Moreover, a 
sensitive enzyme immunoassay (enzyme-linked immunosorbent assay (ELISA)) for the 
determination of TTR values has been described, but this method is more time consuming 
and expensive compared with the above mentioned, and is more applicable, for example, 
for the estimation of TTR in the cerebrospinal fluid in nanogram amounts [43]. In veterinary 
medicine, species-specific ELISA is the most common analytical tool for the detection and 
quantification of transthyretin, utilizing monoclonal anti-TTR antibodies. In some avian spe-
cies, for example, in budgerigars (Melopsittacus undulatus) transthyretin (prealbumin) consti-
tutes as high as 75% of the total albumin concentration [44]. Therefore, it may be visualized 
and quantified easily by protein electrophoresis.
6. Factors influencing the concentrations of TTR
The concentration of TTR in serum is affected by many factors, including age, gender, as well 
as blood-drawing methods. In humans, the concentrations of transthyretin increase gradually 
after birth until they reached the adult values of 20–40 mg/dL [45]. A progressive increase of 
TTR concentrations with postnatal age was reported also by Kanakoudi et al. [46] in infants. 
Similarly, Cardoso and Falção [47] observed a marked increase of TTR concentrations in the 
period from birth till day 28 of age in preterm infants with very low birth weight. According 
to these authors, the serum concentrations of transthyretin in this important period of life are 
associated with the recent protein status, and reflect the balance between synthesis and deg-
radation. Moreover, MacDonald et al. [48] stated that TTR values may predict future weight 
gain and concluded that if the serum concentrations of TTR remain stable or increase, it can 
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be expect that the newborn is in reasonable nitrogen balance and will gain weight subse-
quently. According to Benvenga et al. [49], the concentrations of TTR progressively decrease 
after 50–60 years. Approximately from the year 60 of age, muscle mass undergoes stepwise 
shrinking leading to sarcopenia, which may be responsible for the aforementioned decrease 
in the concentrations of TTR [50, 51]. In animals, the influence of age on the concentrations of 
TTR during the growth and development is not well described. A marked increase of TTR val-
ues from 72.9 to 251.4 mg/L was observed by Tóthová et al. [7] in calves 1 day after colostrum 
intake with a consecutive gradual decrease till the end of the third month of life. Rona [52] 
described that bovine colostrum contains among other bioactive molecules a small amount 
of prealbumin (transthyretin). Thus, the increase of serum TTR concentrations observed in 
calves after colostrum intake may reflect the adequate nutrition, as well as its hepatic syn-
thesis due to adequate protein and energy intake [14]. In neonatal rats, low concentrations of 
TTR were found in the immediate postnatal period, which increases at the time when the con-
centrations of both thyroxine and corticosterone increase [53]. On the other hand, there were 
no significant differences in the serum concentrations of TTR in three different age groups of 
pigs from 10 to 25 weeks [54].
The concentrations of transthyretin linearly increase after birth without marked sexual 
 differences during infant growth [55]. During human puberty, major hormonal and meta-
bolic alterations occur, which result in increased height, weight gain and a substantial redis-
tribution of body tissues. While androgens promote the development of muscle mass in 
male teenagers, oestrogens contribute to minimal enlargement of the female musculature 
and stimulate the accretion of subcutaneous fat depots [56]. These differences lead to higher 
concentrations of TTR in male adolescents compared with values recorded in teenage girls 
[57]. Higher concentrations of TTR in males compared with females were found also by 
Benvenga et al. [49] and Gaggiotti et al. [58]. Studies dealing with the evaluation of gender-
related differences in the concentrations of TTR in animals were not found.
Pregnancy, hormonal changes, physiological status and stress are other factors that may influ-
ence the concentrations of transthyretin. In humans, the concentrations of TTR were evaluated 
by Zhu et al. [59] during normal pregnancy. The values of TTR increased significantly in the 
third month of gestation and rapidly decreased following 20 weeks of gestation. Transthyretin 
was measured also in females with severe preeclampsia, showing significantly decreased TTR 
concentrations in these patients compared with the control group. Transthyretin is synthe-
sized also by placental trophoblasts, which are critical to the normal fetal development. Thus, 
disorders caused by the production of TTR may result in fetal distress [60]. The aforemen-
tioned results indicated that TTR may be a reliable biomarker for the diagnosis of severe pre-
eclampsia [59]. Similarly, Kalkunte et al. [61] suggested a relationship between reduced TTR 
production and preeclampsia. The importance, functional role and alterations in the concen-
trations of TTR during pregnancy in animals have not been reported. Our findings suggest no 
significant changes in TTR concentrations during the last week of pregnancy and early stages 
of lactation in dairy cows (unpublished data). However, further evaluations are needed to 
establish the values of transthyretin and its possible changes in pregnant and lactating cows, 
which may be useful for veterinary practitioners in the early diagnosis, prevention and finding 
therapeutic solutions in periparturient dairy cows.
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In humans, for the measurement of concentrations of TTR, it was recommended to take blood 
samples after 15–20 min in the sitting position [6]. Lower values are expected in bedridden 
patients, while standing position prior to blood sampling may result in higher concentrations.
7. The usefulness of transthyretin in the human clinical practice
7.1. Nutritional marker
Transthyretin may be used as important diagnostic tool for various disease conditions in 
humans, but is more often used as an indicator of malnutrition [62]. Several studies have 
shown a correlation between the concentrations of TTR and nutritional status [63, 64]. 
According to Ingenbleek and Young [14], low TTR concentrations are associated with inade-
quate protein calorie consumption or malnutrition. However, TTR may not serve as a reliable 
nutritional marker in patients with high concentrations of C-reactive protein (CRP), because 
of the activation of inflammatory responses [65]. This may complicate the use of TTR as 
an indicator of nutritional status, since inflammatory processes can lead to the decrease of 
serum TTR concentrations (negative acute phase protein) [66]. The CRP/TTR ratio may be 
a useful index in these cases to differentiate inflammatory states from protein malnutrition 
[67]. Very high ratios (>20) are indicative of acute phase response rather than protein malnu-
trition, while mild inflammatory processes may be accompanied by approximately a 10-fold 
increase in the concentrations of CRP and in CRP/TTR index values [6]. However, an inflam-
matory and nutrition index in animals was not yet established.
Surprisingly, extreme cases of starvation, including anorexia nervosa, have not been associ-
ated with a decrease of TTR concentrations. Nova et al. [68] reported normal values of trans-
thyretin in patients with anorexia nervosa, which were comparable to values found in controls 
and did not differ after nutritional intervention. Barbe et al. [69] stated also that transthyretin 
concentrations in the majority of anorectic patients did not differ from those in control sub-
jects, even in the presence of severe cachexia, but increased after weight gain. On the other 
hand, Gendall et al. [70] found lower concentrations of TTR in women with bulimia nervosa. 
These contradictory data indicate that further studies are needed to determine the effect of the 
aforementioned generalized malnutrition states on the values of transthyretin.
7.2. Disease marker
As transthyretin (prealbumin) belongs to negative acute phase proteins, its serum concentra-
tions may be affected by many disease conditions, including trauma, inflammatory diseases, 
infections or malignancy (Table 1). Patients with severe sepsis or multiple injuries often have 
very low concentrations of TTR, related to severe acute phase response [71]. Studies have 
suggested that TTR may be a sensitive marker for the diagnosis of patients with liver cell 
damage, liver cirrhosis or hepatocellular carcinoma, reflecting the impaired liver synthetic 
function [72, 73]. Hutchinson et al. [74] and Yasmin et al. [75] found significantly lower con-
centrations of TTR in various types of chronic liver diseases when compared with controls 
with no impairment of liver functions. Moreover, Liu et al. [72] reported significantly lower 
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TTR values in patients who died compared to survivors suggesting its role in predicting the 
prognosis of patients with decompensated liver cirrhosis.
Pneumonia in children caused by Mycoplasma pneumonia was also associated with lower TTR 
 concentrations compared to a healthy control group [76]. Similarly, Luo et al. [77] recorded reduced 
TTR values in patients with tuberculosis and lung cancer, while the serum concentrations of TTR 
were lower in patients suffering from tuberculosis than in patients with lung cancer. Moreover, the 
changes in TTR values were in accordance with the therapeutic effects of anti-tuberculosis drugs, 
which may be useful by the monitoring of therapy in these patients. However, seeing that nutri-
tional imbalance is very common in patients with tuberculosis and after chemotherapy in subjects 
with lung cancer, poor performance status should be taken into consideration when interpreting 
serum TTR values in these patients and should be further investigated.
The concentrations of transthyretin may be altered also by thyroid diseases, especially 
endemic goitre [6]. Low concentrations of TTR were found by Vergani et al. [78] in patients 
with untreated thyrotoxicosis, but the values recorded in the majority of cases with untreated 
hypothyroidism were within normal range. The concentrations of transthyretin were mea-
sured also by Ishida et al. [79] in patients with various thyroidal states. In patients with 
untreated hyperthyroidism, markedly low serum TTR values were found, but were normal-
ized by treating with anti-thyroid drug. Similarly, the aforementioned authors observed 
markedly low TTR concentrations in patients with subacute thyroiditis, but in patients with 
hypothyroidism the TTR values were within the normal range.
Changes in the concentrations of TTR were evaluated also in subjects affected by protein-
losing enteropathy, which is characterized by marked losses of serum proteins through the 
bowel wall into the gastrointestinal tract resulting in hypoproteinaemia [80]. Despite hypo-
proteinaemia, Takeda et al. [81] observed TTR values within the normal range in patients 
with protein-losing gastroenteropathy. This phenomenon may be explained by the slightly 
increased production of rapidly turned-over proteins (including TTR) by the liver in response 
to the gastrointestinal losses.
Alteration Associated disease condition
Decrease Inflammatory diseases, infections, trauma, malignancy
Severe sepsis, multiple injuries
Liver cell damage, liver cirrhosis, hepatocellular carcinoma, chronic liver 
diseases
Thyroid diseases, endemic goitre
Protein-losing enteropathy
Chronic malnutrition
Increase Dehydration
Chronic renal failure, renal insufficiency
Anti-inflammatory therapy, anabolic steroids
Acute alcohol intoxication
Hodgkin´s lymphoma, pancreatic cancer
Table 1. Abnormalities in the serum concentrations of transthyretin and associated diseases (adapted from Ref. [6]).
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Increased serum concentrations of transthyretin are typically associated with chronic renal 
failure, presumably due to the decreased tubular uptake and degradation of RBP [82]. Cano 
[83] stated also that chronic renal failure may result in an increase of serum TTR concentra-
tions, but these elevated TTR values during renal insufficiency are secondary to the lack of 
RBP degradation in renal tubules and to the subsequent increase in TTR. The concentrations 
of TTR may rise also during corticosteroid therapy and administration of anabolic steroids, 
as well as in patients using anti-inflammatory agents [6, 84]. Young et al. [85] found increased 
concentrations of TTR in ill-surgical patients receiving anabolic steroids, which may enhance 
amino acid and water uptake by tissues and increase the utilization of fat. Increased TTR con-
centrations may be seen in acute alcohol intoxication, caused by the leakage of proteins from 
damaged hepatic cells [86]. Transthyretin was shown to be upregulated also in Hodgkin´s 
lymphoma and pancreatic cancer [11, 87].
7.3. Prognostic indicator
Several studies evaluated the significance of TTR as a prognostic biomarker and suggested that 
low concentrations may be associated with poor prognosis [88, 89]. Transthyretin was found 
as a prognostic factor for treatment outcomes and/or nutritional status of colon, oesophagus, 
ovarian and lung cancers [90–92]. In these studies, the concentrations of TTR correlated with 
response to treatment and clinical outcomes. Ho et al. [93] reported that low values of TTR 
may serve as prognostic factor for overall survival in cancer patients. However, the interpre-
tation of its values in patients with systemic inflammatory response may be challenging. In 
these conditions, further clinical assessments and laboratory assays may be helpful, including 
markers of inflammation such as C-reactive protein, erythrocyte sedimentation rate or white 
blood cell number.
According to Cheng et al. [94], TTR has also been identified as a significant predictor 
of clinical outcomes after surgical intervention. Therefore, it may be used as part of the 
blood screening completed before surgery to determine pre-surgery health. Low TTR val-
ues before surgery may be associated with an increased risk of complications, including 
infections or pneumonia. Devakonda et al. [88] reported that surgery patients with low 
preoperative TTR values had significantly longer hospital duration of stay and longer 
intensive care unit duration of stay. Moreover, low concentrations of transthyretin were 
associated with higher rates of infectious complications, mortality and other surgical 
complications [95, 96].
8. The usefulness of transthyretin in veterinary medicine
Despite the physiological importance of transthyretin in health and as disease marker, there 
are only a few studies analysing its usefulness in the clinical and laboratory diagnosis of 
diseases in animals. Studies performed in dogs suggested that not only quantitative but also 
qualitative differences exist between human and canine TTR [97]. Transthyretin from dog 
plasma was of lower molecular mass compared to human TTR in samples subjected to sodium 
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dodecyl-polyacrylamide gel electrophoresis with subsequent Western blot analysis [98]. 
Piechotta et al. [99] investigated the serum concentrations of TTR in dogs with nonthyroidal 
illness (including neoplasia, allergy, cardiac disease, gastrointestinal disease, parasitism and 
hepatic disease) and low T4 concentrations compared with those in healthy dogs and dogs 
with primary hypothyroidism. They found significantly decreased serum concentrations of 
TTR in dogs with nonthyroidal illness (24.8 mg/L) compared with its concentration in hypo-
thyroid dogs (41.1 mg/L). On the other hand, significant differences in TTR values were not 
found between hypothyroid and healthy dogs, or between dogs with nonthyroidal illness and 
healthy dogs. In the study presented by Raila et al. [100], low concentration of TTR was found 
in a young dog with chronic renal failure, probably caused by its increased urinary excre-
tion. Changes in the serum concentrations of TTR were observed also in rats during protein-
energy malnutrition [62]. The mean value of transthyretin in healthy pig serum obtained by 
Campbell et al. [54] was 302 ± 8 mg/L, but following Streptococcus suis type 2 infection the 
concentrations markedly decreased. In horses, transthyretin was identified using immunodif-
fusion technique, but the study was performed many years ago [101]. Establishing a quantita-
tive method, such as an enzyme immunoassay, to measure the concentrations of TTR may be 
useful also in horses. In cattle, there are very little published reports about the usefulness of 
transthyretin in the diagnosis of diseases. Our preliminary results suggest lower concentra-
tions of TTR in diarrhoic calves at the age of 1 month compared with healthy animals at the 
same age. Similarly, Mycobacterium avium paratuberculosis seropositive cows showed lower 
TTR values than those obtained in healthy cattle (unpublished data). Chang et al. [102] have 
isolated and sequenced transthyretin not only in humans and other mammalian species but 
also in birds, including emu, chicken, ostrich and pigeon. This study showed that TTR has 
greater than 98% homology and has a very similar binding pattern across species. However, 
additional studies should be done to determine the effect of various diseases on the serum 
concentrations of TTR in animals.
9. Conclusions
Presented data suggest that transthyretin may contribute to the evaluation of health state and 
diagnosis of some diseases also in animals. Changes in serum concentrations of TTR may be 
indicative of inadequate nutrient intake and may serve as an additional diagnostic tool for 
clinicians in the evaluation of some pathological conditions. It may be used as an integral part 
of the overall health assessment or in hospitalized animals to evaluate their nutritional status 
during the treatment and recovery. Low serum TTR concentrations may be considered a sign 
of increased risk of malnutrition, requiring further nutritional assessment.
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